HEALABS

What HEALABS does

HEALABS (legal entity SAS Healabs) is a privately held French digital health company headquartered in Beaumont-lès-Valence with a secondary office in Lyon. The company develops and commercializes ApTeleCare, a Class I medical device software platform for remote patient monitoring (télésurveillance médicale) of chronic diseases. ApTeleCare is a 100% adaptable, multi-pathology platform supporting renal insufficiency, cardiac insufficiency, respiratory insufficiency, stroke recovery, depression, nephrotic syndrome, and congenital heart disease applications. Technical capabilities include structured patient data collection via questionnaires, automatic ingestion from connected medical devices (scales, blood pressure monitors, thermometers), real-time threshold-based alerting for clinicians, secure patient-provider messaging, therapeutic education delivery, and AI-powered data analysis. The platform integrates with French DPI (Dossier Patient Informatisé), shared medical records, laboratory systems, and teleconsultation tools.

The business operates three revenue streams: (1) subscription-based telesurveillance licensing to French healthcare establishments under the L.162-52 reimbursement framework for kidney, cardiac, and respiratory indications; (2) clinical study services for research institutions conducting post-market surveillance and clinical performance studies; and (3) Digital Therapeutics (DTx) licensing, priced at €435 TTC for the initial 3-month package followed by €38.30/month, capped at €780 TTC annually per patient. GTM is primarily direct enterprise sales targeting French hospitals (CHU Saint Etienne, CHU Lille, CHU Bordeaux, Henri Mondor, Necker-Enfants Malades), home healthcare providers (Santélys, Aura Santé), dialysis networks (CALYDIAL since 2013), and medical device laboratories (Healthy Mind). HEALABS acquired the ApTeleCare activity from TMM Software in 2023, integrating the existing team and client portfolio. The company holds ANS definitive certifications for three reimbursed pathologies, CE marking, HDS, HAS, ISO, and ISO 27001 certifications.

Name

HEALABS

Legal name

SAS Healabs

Website

https://healabs.fr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

HEALABS (SAS Healabs) is a French digital health company developing ApTeleCare, a Class I reimbursable medical device platform for remote patient monitoring of chronic diseases including renal, cardiac, and respiratory insufficiency, serving French hospitals, home healthcare providers, and medical device laboratories.

Ownership category

akta.pro rank

Headquarters

HQ city

Beaumont-lès-valence

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Telesurveillance Software Licensing: ApTeleCare is a reimbursable medical device (Class I) on the French health insurance list L.162-52 for chronic kidney, cardiac, and respiratory diseases. Revenue comes from healthcare establishment subscriptions for telemedicine services.
2. Clinical Study Services: The company provides its platform for clinical studies conducted by healthcare institutions, supporting data collection, patient monitoring, and outcomes tracking.
3. Digital Therapeutics Engine (DTx): HEALABS positions ApTeleCare as a regulated DTx engine for creating branded telemedicine solutions, generating licensing revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

HEALABS develops and commercializes ApTeleCare, a CE-marked Class I medical device telemonitoring platform that enables healthcare professionals to remotely monitor patients with chronic diseases (renal, cardiac, respiratory, post-stroke, depression, nephrotic syndrome). The platform supports patient questionnaires, secure messaging, therapeutic education content, connected-device data capture, and automated alerts, and is reimbursable under French social security list L.162-52. The company also licenses ApTeleCare as a Digital Therapeutics (DTx) engine to medical device and pharmaceutical laboratories for branded telemedicine solutions and clinical study support.

Product overview

HEALABS offers a unified digital health platform centered on ApTeleCare, a multi-pathology telemonitoring medical device. ApTeleCare serves as the core platform providing remote patient monitoring capabilities including health data collection via questionnaires, secure patient-provider messaging, therapeutic education content delivery, and real-time alerts for healthcare teams. The solution is designed to be fully adaptable and customizable across multiple chronic disease indications including chronic kidney disease, heart failure, respiratory insufficiency, and others.

Differentiator

Problem solved

Functional benefit

Products and services

• ApTeleCare CE-marked Class I medical device telemonitoring platform that enables healthcare professionals to remotely monitor patients with chronic diseases. Allows patients to input health data via questionnaires, ask questions through secure messaging, access therapeutic education content, and transmit measurements from connected devices (scales, blood pressure monitors, thermometers). Includes real-time automated alerts when patient parameters exceed defined thresholds and supports multiple pathologies including chronic kidney disease, heart failure, respiratory insufficiency, post-stroke recovery, depression, and nephrotic syndrome.

Quantifiable outcome

• Reduction in unplanned hospitalizations - MEDIA study evaluating impact of telesurveillance on home dialysis patients
• +2 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability1 record

Feature6 records

Partnerships

13 partnerships are on record, tiered core and minor.

• PromantiscoreStrategic or Co-development Partner · 4 March 2024Partnership announced March 4, 2024 for cardiac telesurveillance. Promantis provides expertise in telecardiology with its My-Promantis platform offering multi-brand connectivity for cardiac prostheses monitoring. HEALABS contributes ApTeleCare as multi-pathology telesurveillance engine. Together they aim to improve care for patients with cardiac rhythm problems and heart failure, covering approximately 400,000 patients in France with cardiac prostheses.
• Healthy MindminorStrategic or Co-development PartnerMedical device company developing VR-based solutions for pain and anxiety reduction. Uses ApTeleCare as digital follow-up component in clinical studies, particularly in palliative care settings. Partnership enables post-market surveillance (PVRC) data collection and clinical performance studies.
• AMSN (Association des Malades d'un Syndrome Néphrotique)coreStrategic or Co-development PartnerPatient association for nephrotic syndrome, member of ORKD health network. Jointly developed ApTeleCare solution for nephrotic syndrome with scientific committee. Project aims to improve patient follow-up, create database, and potentially request national reimbursement.
• CALYDIALcoreStrategic or Co-development PartnerFirst customer since 2013, private non-profit kidney health and dialysis facility. Collaborated on ApTeleCare development for home dialysis and NeLLY service for chronic kidney disease stages 3B-4. Multiple clinical studies conducted including PRME NELLY.
• CHU LilleminorStrategic or Co-development PartnerUniversity hospital participating in Kidshearts project for monitoring neurodevelopment of infants with congenital heart disease using ApTeleCare as digital health diary.
• Sigvaris GroupminorStrategic or Co-development PartnerFrance 2030 funded Symphonies project (9.8M euro budget). Sigvaris leads development of smart compression textiles for lymphedema. HEALABS develops technology for data transmission and AI-powered platform integrating connected textile data.
• IFTH (Institut Français du Textile et de l'Habillement)minorStrategic or Co-development PartnerPart of Symphonies consortium for smart textile development. Technical expertise for textile innovation.
• Ecole des Mines de Saint-EtienneminorStrategic or Co-development PartnerSAINBIOSE laboratory partner in Symphonies project. Bioengineering and numerical simulation expertise.
• ENSAITminorStrategic or Co-development PartnerGEMTEX laboratory partner. Leading French textile research laboratory and simulation expert.
• INSA LyonminorStrategic or Co-development PartnerINL (Institut des Nanotechnologies de Lyon) partner with biomedical sensors group expertise.
• TMM SoftwarecoreOEM/ Whitelabel/ Licensing PartnerHEALABS acquired ApTeleCare software activity from TMM Software in 2023. ApTeleCare was created in 2013. Acquisition included continuity of team and customer base.
• Hôpitaux Universitaires Henri MondorcoreStrategic or Co-development PartnerReference center for rare nephrotic syndrome (SNI) in children and adults. Professor Vincent Audard leads scientific committee for nephrotic syndrome telesurveillance project.
• Hôpital Universitaire Necker-Enfants MaladescoreStrategic or Co-development PartnerProfessor Olivia Boyer leads nephrotic syndrome project. Center de Référence Maladie Rare SNI collaboration.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Doctolib: Dominant French health-tech platform offering appointment booking, teleconsultation, and increasingly patient management software. Comparable as a broad French digital-health incumbent whose teleconsultation and patient-record modules could overlap with parts of ApTeleCare's offerings, though it does not specialize in multi-pathology telesurveillance.
• Teladoc Health (Livongo): Global leader in virtual care and chronic-condition management (including diabetes, hypertension) following Livongo acquisition. Comparable to HEALABS as a chronic-disease RPM platform, but operates at a much broader global scale across multiple conditions.
• Withings Health Solutions: French connected-devices company offering RPM hardware (blood pressure monitors, scales, sleep) plus a B2B health solutions platform. Comparable to HEALABS's connected-device integration strategy for RPM and chronic-disease monitoring, though Withings plays a broader supplier role across multiple RPM software platforms.

Direct peers

• Newcard: French telemedicine and telesurveillance platform focused on chronic disease management (heart failure, COPD, diabetes) reimbursed under French L.162-52. Closely comparable to ApTeleCare as a direct French RPM competitor serving hospitals, HAD providers, and cardiology clinics with ANS-certified software.
• Bioserenity: French connected-health company developing wearable RPM solutions for cardiology, neurology, and sleep disorders with integrated AI analysis. Comparable to HEALABS in multi-pathology connected-care and French/EU RPM reimbursement positioning, with similar partnerships to pharmaceutical and medical-device laboratories.
• H2AD: French healthcare-at-home and telesurveillance operator providing remote monitoring services to HAD providers and hospitals. Comparable to HEALABS's HAD-customer segment and French RPM focus, particularly in chronic disease management and home monitoring.
• Implicity: French remote cardiac monitoring platform for pacemaker/ICD patients, offering a cloud-based platform with multi-brand device connectivity. Directly comparable to HEALABS via ApTeleCare's cardiac telesurveillance partnership with Promantis, both serving the French reimbursement-driven RPM market for chronic cardiac patients.
• Cureety: French telemonitoring platform for oncology patients with reimbursement under French framework. Directly comparable to HEALABS as a French telesurveillance solution reimbursed under right-commun, targeting hospital-based chronic disease monitoring.
• Voluntis: French digital therapeutics company developing companion software for chronic conditions (diabetes, oncology), later acquired by AptarGroup. Comparable to HEALABS's positioning as a DTx engine for pharma/medical-device partners, with similar regulatory and reimbursement pathways in Europe.

Emerging players

• Observia: French health-tech company providing digital patient engagement and therapeutic adherence solutions for chronic diseases. Comparable to HEALABS's therapeutic-education, adherence-monitoring, and DTx components, though focused on engagement software rather than full telesurveillance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/healabs/about

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEALABS